The safety and efficacy of left atrial appendage closure, as compared with oral anticoagulation, in patients at elevated stroke risk undergoing atrial fibrillation ablation have been unclear.

Though ischemic outcomes numerically favored the Amulet, confirmation in future studies is needed, experts say.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

John Mandrola questions the conclusions and fears the rise in percutaneous left atrial appendage closure procedures. Commentary, November 18, 2024 AHA 2024 The Most Worrisome Study at AHA 2024 A ...

North America is expected to dominate the atrial appendage occluder market, with a market share of 39.8%. The region’s large geriatric population and the high number of stroke-related deaths ...

Med Tech & Diagnostics Analysts, along with Dr. Rahul Doshi, an electrophysiology expert, discuss ablation, left atrial appendage closure, ...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...